SCHEMBL6304381

SCHEMBL6304381

CCc1c(C(=O)O)nc(C(=O)O)c(CC)c1N1CCNCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2A Q9UIF9 2/20 0.39
ITGA2B P08514 3/20 0.36
ITGB3 P05106 2/20 0.36
LMNA P02545 3/20 0.36
CYP2C9 P11712 1/20 0.36
ATP6V1B2 P21281 1/20 0.36
TBXA2R P21731 1/20 0.36
EDNRA P25101 1/20 0.36
TARBP2 Q15633 1/20 0.36
HTR2C P28335 2/20 0.35
HTR2B P41595 1/20 0.35
ALDH1A1 P00352 3/20 0.34
HSD17B10 Q99714 3/20 0.34
KDM4E B2RXH2 2/20 0.34
TSHR P16473 2/20 0.34
HRH4 Q9H3N8 1/20 0.34
BRD4 O60885 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
CYP2J2 P51589 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6304377 0.92 BAZ2A (0.38) BAZ2AITGA2BITGB3LMNACYP2C9
SCHEMBL5457164 0.74 NUDT1 (0.46) LMNAHTR2CALDH1A1HSD17B10KDM4E
SCHEMBL15414822 0.74 LMNA (0.35) BAZ2AITGA2BITGB3LMNACYP2C9
SCHEMBL2339894 0.73 HRH1 (0.39) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL874422 0.71 HRH1 (0.41) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL30297090 0.70 ADRB1 (0.43) HTR2CALDH1A1HSD17B10KDM4EHPGD
SCHEMBL15415184 0.69 KDM4E (0.38) BAZ2AITGA2BITGB3LMNACYP2C9
SCHEMBL31357304 0.69 TSHR (0.43) ALDH1A1HSD17B10KDM4ETSHRHPGD
SCHEMBL5188179 0.68 HCAR2 (0.41) ALDH1A1HCAR2
SCHEMBL5448462 0.67 TSHR (0.37) LMNAALDH1A1HSD17B10KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6942966-B1 libraries formed by permutations; combinatorial chemistry; drug screening ISIS PHARMACEUTICALS, INC. (US) 2005-09-13 US disclosed
US-6559303-B1 Bridgehead atoms are bonded to one or more bridges that interconnect one or more ring systems thereby forming a large cyclic structure. Located in each bridge are two or more nitrogenous moieties that are derivatized with chemical ISIS PHARMACEUTICALS, INC. 2003-05-06 US disclosed
US-6329523-B1 FOR ANTIBACTERIAL PHARMACEUTICAL USE, USEFUL FOR IDENTIFYING METAL CHELATING SPECIES FOR ?HEAVY METAL? THERAPY; IMAGING AGENTS ISIS PHARMACEUTICALS, INC. 2001-12-11 US disclosed
US-6197965-B1 POLYARYLALKYLAMINO-SUBSTITUED PYRIDINE DERIVATIVES; DRUGS, MEDICINE, DIAGNOSTICS ISIS PHARMACEUTICALS, INC. 2001-03-06 US disclosed
EP-0817787-A4 NITROGENOUS MACROCYCLIC COMPOUNDS ISIS PHARMACEUTICALS INC (US) 2000-09-13 EP disclosed
US-6107482-A LARGE CYCLIC STRUCTURES INTERRUPTED BY AT LEAST ONE RING SYSTEM WHICH INCLUDES TWO BRIDGEHEAD ATOMS; CONTAIN PLURALITY NITROGENOUS SITES THAT ARE DERIVATIZED SUCH AS WITH DRUGS, NUCLEIC ACIDS, PROTEINS; USE IN LIBRARIES ISIS PHARMACEUTICALS, INC. (US) 2000-08-22 US disclosed
US-6077954-A COMPOUNDS ARE CONSTRUCTED TO INCLUDE A CENTRAL AROMATIC, ALIPHATIC, OR HETEROCYCLIC RING SYSTEM. ATTACHED TO THE CENTRAL RING SYSTEM ARE TWO LINEAR GROUPS HAVING NITROGENOUS MOIETIES THAT ARE DERIVATIZED WITH CHEMICAL FUNCTIONAL GROUPS. ISIS PHARMACEUTICALS, INC. (US) 2000-06-20 US disclosed
WO-1998010286-A1 METHODS FOR PROCESSING CHEMICAL COMPOUNDS HAVING REACTIVE FUNCTIONAL GROUPS ISIS PHARMACEUTICALS, INC. (US) 1998-03-12 WO disclosed
WO-1998005961-A1 COMPOUNDS HAVING A PLURALITY OF NITROGENOUS SUBSTITUENTS ISIS PHARMACEUTICALS, INC. (US) 1998-02-12 WO disclosed
EP-0817787-A1 NITROGENOUS MACROCYCLIC COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 1998-01-14 EP disclosed
WO-1996030377-A1 NITROGENOUS MACROCYCLIC COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 1996-10-03 WO disclosed